Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports
Abstract Background Recently, there have been significant advances in the treatment of spinal muscular atrophy (SMA). Although clinical improvement in patients with SMA after the treatment has been reported, changes in electrophysiological findings, especially needle electromyography (EMG), have rar...
Main Authors: | Tomoko Mizuno, Tadashi Kanouchi, Yumie Tamura, Ko Hirata, Runa Emoto, Tomonori Suzuki, Kenichi Kashimada, Tomohiro Morio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-023-03420-2 |
Similar Items
-
Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi
by: Marina Flotats-Bastardas, et al.
Published: (2023-12-01) -
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021-01-01) -
Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
by: Georg M. Stettner, et al.
Published: (2023-02-01) -
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
by: Charlotte A. René, et al.
Published: (2023-06-01) -
Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
by: Ramos-Platt L, et al.
Published: (2022-09-01)